NEO-FER CF CAPSULES
Natural health product licensed in Canada
- Licence holder
- Neobourne Pharma LP
- NPN or DIN-HM
- 02190370
- Status
- Inactive licence
- Licence date
- 12 May 2008
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine C: up to 200 mg a day according to the dosing instructions published by Health Canada (1 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitamine C Source : Acide ascorbique | 200 mg | 200,000 µg |
Non-medicinal ingredients
FD & C Rouge # 40, FD & C bleu #1, D&C Red #28, Talc, Stéarate de magnésium, Amidon, Dioxyde de titane, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Treatment of iron deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Hemosiderosis, hemochromatosis, hemolytic anemia.
- Effets indésirables connus
Gastrointestinal irritation in iron sensitive patient.
- Précautions et mises en garde
Increased capillary permeability, reduced plasma volume, increased cardiac output and sudden cardiovascular collapse may occur in acute iron intoxication. Oral preparations may aggravate exisiting peptic ulcer regional enteritis and ulcerative colitis. Iron compounds taken orally can impair the absorption of tetracycline antibiotics. Antacids given concomitantly with iron compounds decrease iron absorption.
Source
Official Health Canada record, licence 02190370
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.